Chance Osborne Discovers Triple Negative Breast Cancer Despite Regular Screening
I thought I was maybe laying on like a seashell or something, so I went to go lift up my beach towel, and there was nothing there. And I will never forget that feeling in my stomach of like, ‘oh no,’
Chance Osborne recalled of finding a fast-growing lump while vacationing in Florida, USA TODAY Network reported. Osborne, diagnosed with BRCA1 at age 18 following a family history of breast and ovarian cancer, began rigorous bi-annual imaging at age 20 that included breast MRIs, mammograms, and ultrasounds. Despite a clean breast MRI in early 2021, she developed triple negative breast cancer at age 24 that doubled in size within a two-week span.
Treatment Timeline and Preventive Surgeries Followed the 2021 Diagnosis
Following her diagnosis in early 2021, Osborne underwent an extensive medical regimen that started with chemotherapy from April to August 2021. According to USA TODAY Network, her treatment plan included subsequent surgery, radiation therapy, a double mastectomy with failed reconstruction, and a total hysterectomy performed as a preventative measure due to her BRCA1 status and family history of ovarian cancer. She also completed 372 days of medication, reaching five years of survival by 2026.
Rising Cancer Rates in Younger Demographics Shape Broader Health Concerns
Osborne’s diagnosis highlights a broader epidemiological shift documented by American Cancer Society research published in 2024, which shows breast, liver, ovarian, and colorectal cancers rising among Gen X and millennial populations. USA TODAY Network noted that breast cancer remains the most common cancer for U.S. women apart from skin cancer, with over 300,000 new diagnoses expected annually and a projected death toll exceeding 40,000 women in 2026.
Oncologist Recommends Screening and Early Detection Protocols
Addressing common public misconceptions, Dr. Ruemu Birhiray, an oncologist and hematologist at Hematology Oncology of Indiana and the American Oncology Network, stated via USA TODAY Network that a family history is not required to develop breast cancer. Birhiray advises patients to perform monthly self-breast exams and undergo annual mammograms, noting that while screening tools are not perfect, they remain vital for identifying early-stage disease where most breast cancers are curable.
Circulating Tumor Data Testing Provides Ongoing Monitoring for Relapse
Seeking methods to detect potential cancer recurrence early, Osborne utilized online patient communities to discover Signatera, a circulating tumor DNA test produced by Natera, where she is now employed. USA TODAY Network reported that Osborne undergoes the blood test every three months—anticipating a switch to twice a year after reaching seven years cancer-free—and has recorded 15 negative results under the guidance of her oncologist.
Frequently Asked Questions About BRCA1-Associated Breast Cancer
What is the BRCA1 gene and how does it affect cancer risk?
BRCA1 is a genetic mutation that significantly increases an individual’s lifetime risk of developing breast and ovarian cancers. Carriers often begin intensified screening protocols, such as alternating MRIs and mammograms, at an early age.
How fast does triple negative breast cancer grow?
Triple negative breast cancer is known to grow extremely fast compared to other types of breast cancer. In Osborne’s case, reported by USA TODAY Network, her tumor nearly doubled in size within a two-week window shortly after a clear imaging scan.
What preventative surgeries are common for BRCA1 carriers?
Carriers of the BRCA1 gene often consider risk-reducing surgeries such as preventative double mastectomies and total hysterectomies. Osborne underwent both procedures following her diagnosis to mitigate her high genetic risk for breast and ovarian malignancies.
What is a circulating tumor DNA test?
A circulating tumor DNA test, such as Signatera, analyzes blood samples to detect fragments of tumor DNA left behind in the bloodstream. Patients use these tests to monitor for potential cancer relapses earlier than traditional imaging allows.
Keep reading